Abstract: Anomalies in network traffic are detected using machine learning. A plurality of machine learning models is employed to determine whether there are anomalies in network traffic of an MPLS (Multiprotocol Label Switching) network that can affect the performance of devices in the network. A first machine learning model is trained on network traffic passed through network tunnels of a plurality of routers in the network. A second machine learning model is trained on router-specific network traffic passed through router-specific network traffic for a subset of the network tunnels associated with a particular router. The first machine learning model is employed to determine a network anomaly, and the second machine learning model is employed to determine a router-specific anomaly. A router error is identified when both a network anomaly and a router-specific anomaly are determined. An indication of the router error is communicated to a computing device.

Abstract: The invention relates to a single unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

Abstract: Anomalies in network traffic are detected using machine learning. A plurality of machine learning models is employed to determine whether there are anomalies in network traffic of an MPLS (Multiprotocol Label Switching) network that can affect the performance of devices in the network. A first machine learning model is trained on network traffic passed through network tunnels of a plurality of routers in the network. A second machine learning model is trained on router-specific network traffic passed through router-specific network traffic for a subset of the network tunnels associated with a particular router. The first machine learning model is employed to determine a network anomaly, and the second machine learning model is employed to determine a router-specific anomaly. A router error is identified when both a network anomaly and a router-specific anomaly are determined. An indication of the router error is communicated to a computing device.

Abstract: Systems and methods for making telecommunication network predictions on a granular geographic area-scale. The method can include receiving network key performance indicators (KPIs) associated with a plurality of user equipment (UEs) and then parsing the network KPIs into a plurality of geographic area-based categories corresponding to network KPIs obtained by cell towers or UEs located within a given geographic area, like a zip code. The method can further include combining the geographic area-based categories into clusters determined based on one or more similarities in the network KPIs of each, and predicting a most-influential one of the network KPIs within at least one of the clusters via a machine learning (ML) model. In response, the method can then cause an indicator to be generated at a user interface, the indicator indicating the most-influential one of the network KPIs within the at least one of the clusters.

Abstract: Anomalies are detected in network traffic exhibiting a seasonal variation. A neural network is trained using historical network traffic metrics, and as a result, the trained neural network is configured to output a mean error from a network traffic metric input. A decision tree model is trained on a training dataset comprising historical network traffic metric outputs at associated times. To identify an anomaly, network traffic metrics for a particular time are provided as an input to the trained neural network that, in response, outputs the mean error. The particular time is input into the trained decision tree model to output a mean error adjustment. The mean error is adjusted using the mean error adjustment, and the resulting adjusted mean error is compared to a static mean error threshold value to identify the anomaly.

Abstract: The invention relates to a method for preventing dengue disease and hepatitis A in a subject or subject population by simultaneously administering a unit dose of a dengue vaccine composition and a hepatitis A vaccine on the same day. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

Abstract: The invention relates to a method for preventing dengue disease and hepatitis A in a subject or subject population by simultaneously administering a unit dose of a dengue vaccine composition and a hepatitis A vaccine on the same day. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

Abstract: Embodiments herein concern compositions, methods, and uses for inducing an immune response to all four dengue virus serotypes in a child or young adult from about 1 year to about 20 years of age. Some embodiments concern compositions that can include dengue virus chimeras that, either alone or in combination with other constructs, can be used in vaccine compositions against all four dengue virus serotypes. Compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) virus and/or dengue-4 (DEN-4) virus, at various concentrations or ratios to improve protection from infection in children and young adults. In certain embodiments, viruses of the formulations are limited to dengue virus serotypes. Other embodiments concern methods of administering immunogenic compositions against dengue virus that can include chimeric dengue constructs and live, attenuated dengue viruses using single, dual or other regimens.

Abstract: Embodiments herein concern compositions, methods, and uses for inducing an immune response to all four dengue virus serotypes in a child or young adult from about 1 year to about 20 years of age. Some embodiments concern compositions that can include dengue virus chimeras that, either alone or in combination with other constructs, can be used in vaccine compositions against all four dengue virus serotypes. Compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) virus and/or dengue-4 (DEN-4) virus, at various concentrations or ratios to improve protection from infection in children and young adults. In certain embodiments, viruses of the formulations are limited to dengue virus serotypes. Other embodiments concern methods of administering immunogenic compositions against dengue virus that can include chimeric dengue constructs and live, attenuated dengue viruses using single, dual or other regimens.

Abstract: The invention relates to a method for preventing dengue disease and hepatitis A in a subject or subject population by simultaneously administering a unit dose of a dengue vaccine composition and a hepatitis A vaccine on the same day. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

Abstract: Embodiments herein concern compositions, methods, and uses for inducing an immune response to all four dengue virus serotypes in a child or young adult from about 1 year to about 20 years of age. Some embodiments concern compositions that can include dengue virus chimeras that, either alone or in combination with other constructs, can be used in vaccine compositions against all four dengue virus serotypes. Compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) virus and/or dengue-4 (DEN-4) virus, at various concentrations or ratios to improve protection from infection in children and young adults. In certain embodiments, viruses of the formulations are limited to dengue virus serotypes. Other embodiments concern methods of administering immunogenic compositions against dengue virus that can include chimeric dengue constructs and live, attenuated dengue viruses using single, dual or other regimens.